Iron Nanoparticle Eliminates Tuberculosis in Mice and May Pave the Way for New Treatments

Why It Matters

A curative, short‑duration TB therapy would boost patient adherence, lower resistance risk, and ease the financial strain on public health systems worldwide.

Key Takeaways

• Iron nanoparticle cleared mouse TB infection in 30 days.
• Lipid encapsulation stabilizes ferroin for controlled release.
• Enhances rifampicin and pretomanid activity, targets cell wall.
• Potential low‑cost, non‑patented therapy for drug‑resistant TB.
• Human trials needed to confirm safety and efficacy.

Pulse Analysis

Tuberculosis remains the leading bacterial killer worldwide, with the WHO reporting up to 50 % mortality without therapy and an 85 % cure rate only when lengthy regimens are completed. Standard protocols demand at least six months of daily multidrug therapy, and multidrug‑resistant strains can push treatment beyond two years, eroding patient adherence and fueling resistance. Health systems, especially in high‑burden countries like Brazil, struggle to maintain supply chains and support vulnerable populations, creating a persistent demand for shorter, safer regimens that can be deployed at scale.

The research team at São Paulo State University repurposed ferroin, an inexpensive iron‑phenanthroline complex first synthesized in the 1950s, by encapsulating it within a nanostructured lipid carrier. This formulation, LNP@FEP, shields the compound from gastric degradation and provides a sustained release profile. In vitro assays showed potent inhibition of Mycobacterium tuberculosis and synergistic effects with rifampicin and pretomanid, while electron microscopy revealed disrupted cell‑wall synthesis reminiscent of β‑lactam action. When administered to infected mice for 30 days, both free and lipid‑encapsulated ferroin achieved complete bacterial clearance in lung tissue, outperforming standard isoniazid.

If subsequent toxicology and pharmacokinetic studies confirm safety, the non‑patented status of ferroin could accelerate public‑sector manufacturing and keep costs low for national health programs. A shorter, less toxic regimen would improve adherence, curtail the emergence of resistant strains, and reduce the economic burden on health services. Moreover, the success of this drug‑repositioning approach underscores the value of revisiting legacy chemicals with modern delivery platforms, a strategy that could revitalize pipelines for other entrenched infectious diseases.